Aigner K, Hild P, Breithaupt H, Hundeiker M, Schwemmle K, Henneking K, Illig L, Merker G, Paul E, Brodkorb J, Jungbluth A
Anticancer Res. 1983 Mar-Apr;3(2):87-93.
Dacarbazine (DTIC) was used for isolated perfusion of extremities in dogs and man. In the animal experiment perfusions with DTIC at dosages up to 100 mg per kg of extremity weight were well tolerated. The concentration of DTIC in the perfusate ranged from 70 to 400 micrograms/ml without evidence for formation of metabolites. Electron microscopy, performed 14 days later, revealed a decrease of glycogen in striated muscle cells. Vascular damage was not observed. Five patients with advanced malignant melanoma or soft tissue sarcoma of the extremities were treated by isolation perfusion with 75 to 133 mg DTIC per kg of extremity at 40 degrees C for 60 minutes. A tumor regression of at least 30% was observed.
达卡巴嗪（DTIC）曾用于犬和人体四肢的隔离灌注。在动物实验中，以高达每千克肢体重量100毫克的剂量用DTIC进行灌注，耐受性良好。灌注液中DTIC的浓度范围为70至400微克/毫升，未发现有代谢产物形成的迹象。14天后进行的电子显微镜检查显示，横纹肌细胞中的糖原减少。未观察到血管损伤。5例晚期四肢恶性黑色素瘤或软组织肉瘤患者接受了40℃下每千克肢体75至133毫克DTIC的隔离灌注治疗60分钟。观察到肿瘤至少消退30%。
